Fort Lauderdale, FL – DemeRx has announced the appointment of Michael Snitkovsky as Chief Operations Officer. About DemeRx: DemeRx is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of addiction through the development of neuroplastogen medications that help reset the brains addiction circuitry. The companys primary focus is DMX-1001, an oral formulation of noribogaine described as an innovative neuroplastogen and groundbreaking therapeutic advancement for alcohol use disorder, with early Phase 1a studies and preclinical research indicating a favorable safety profile, effective pharmacokinetics, and potential efficacy across alcohol, opioid, and cocaine addictions. Built on the pioneering research of its founder and CEO, Dr. Deborah Mash, who advanced understanding of noribogaine as the active metabolite of ibogaine, DemeRx positions itself at the forefront of addiction therapeutics by leveraging neuroplasticity and polypharmacology to intervene rapidly in disrupted brain circuits and reduce cravings and compulsive substance use. The company emphasizes rigorous science, cutting-edge clinical development, and experienced leadership in drug development, addiction treatment, pharmaceuticals, and neuroscience, aiming to revolutionize how addiction is treated and contribute to improved public health outcomes for people affected by alcohol and drug abuse. Headquartered in Miami, Florida, DemeRx presents itself as a mission-driven organization committed to delivering innovative, medically supervised treatments that offer new hope to individuals battling substance use disorders.

For more information visit: https://www.demerx.com/

DemeRx
305 south andrews avenue
Fort Lauderdale, FL 33301
Phone: 786-347-3500
LinkedIn: https://www.linkedin.com/company/demerx-inc./

SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved